Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-5: MET097 once weekly in adults with overweight or obesity and type 2 diabetes
2025-523975-48-00Phase 3Authorised
- Sponsor
- Metsera
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 12
01
Overview
Phase 3, randomised trial in obesity and type 2 diabetes mellitus (T2DM) comparing MET097 once weekly with Matching placebo once weekly (2 arms). Primary endpoint: Percent change from baseline in body weight at Week 64. Planned start Apr 2026; status: authorised.
02
Drugs
PF-08653944
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-523975-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523975-48-00.